A Pseudomonas aeruginosa quorum-sensing inducer controls lung permeability in establishing chronic infection via EGFR

Submitted by Anonymous on

Pseudomonas aeruginosa is an opportunistic pathogen that can cause severe infections in immunocompromised patients. N-(3-oxo-dodecanoyl) homoserine lactone (3oc12) is a small quorum molecule that is used to communicate between bacterial cells and between bacteria and the host. However, the exact...

Lung adenocarcinoma harboring uncommon EGFR exon 19 deletion L747_T751del and in cis K754E mutation: a case report and literature review

Submitted by Anonymous on

Abstract E746_A750del, the most common and predominant EGFR exon 19 deletion in non-small cell lung cancer, shows excellent sensitivity to EGFR tyrosine kinase inhibitors. However, other uncommon EGFR exon 19 deletions show varying responses to EGFR-targeted inhibitors. L747_T751del is a...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer...

Design, synthesis, and insilico evaluation of 2-aminothiazole derivatives as potential mTOR and EGFR inhibitors

Submitted by Anonymous on

Abstract A series of 14 novel 2-aminothiazole (1a-1 g, 2a-2 g) derivatives were synthesized effectively and in silico evaluation was performed to find lead candidates as potential inhibitors targeting breast cancer receptors. One-pot three-component synthesis was carried out using different...

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Submitted by Anonymous on

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer December 6, 2025 Dominic Piscitelli Chief Financial Officer Good morning from Singapore, and welcome to the ORIC Pharmaceuticals Enozertinib Program Update Conference Call....

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia...

Submitted by Anonymous on

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Submitted by Anonymous on

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable...

Subscribe to Newsfeed